J&J EVP John Reed Discusses R&D Model, Oncology Deals and Pipeline Growth Potential

John Reed, executive vice president of Innovative Medicine at Johnson & Johnson, brings more than a decade of experience overseeing drug pipelines at three of the world’s largest pharmaceutical companies. His career began after leaving the Sanford Burnham research institute in Southern California, giving him a broad perspective on how early‑stage molecules progress to market.

In a recent interview, Reed outlined J&J’s current R&D strategy, emphasizing a collaborative model that integrates external partnerships with internal discovery teams. He highlighted several recent oncology agreements that aim to broaden the company’s portfolio and accelerate access to promising cancer therapies.

Reed also expressed confidence in the company’s pipeline expansion, noting that a combination of internal innovation and strategic deals positions J&J to address unmet medical needs across multiple therapeutic areas.